Related Experiment Video

Updated: Oct 24, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Liposomal amphotericin B in neonates with invasive candidiasis

H Al Arishi1, H H Frayha, A Kalloghlian

  • 1Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

American Journal of Perinatology
|March 4, 1999
PubMed

Insights

Liposomal amphotericin B (L-Amp B) shows promise for treating invasive fungal infections in premature infants, potentially reducing toxicity. Further clinical trials are needed to confirm its safety and effectiveness in neonates.

Area of Science:

  • Neonatal Medicine
  • Pediatric Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections pose a significant risk to neonates.
  • Liposomal amphotericin B (L-Amp B) is an effective antifungal agent with reduced toxicity in children and adults.
  • Limited data exists on L-Amp B use in the neonatal population.

Observation:

  • Two premature infants with invasive candidiasis (one with concurrent meningitis) were treated with L-Amp B.
  • Case reviews suggest L-Amp B was administered for high-risk neonates.
  • Previous studies on L-Amp B in neonates were summarized.

Findings:

  • L-Amp B demonstrated potential as a therapeutic option for invasive candidiasis in neonates.
  • The formulation may offer an alternative for neonates susceptible to nephrotoxicity and amphotericin B-related adverse effects.
  • Observed outcomes in the case studies align with the known efficacy of L-Amp B.

Implications:

  • Liposomal amphotericin B may be a viable treatment for invasive candidiasis in high-risk neonates.
  • Further clinical trials are essential to establish the definitive safety and efficacy profile of L-Amp B in this vulnerable age group.
  • This research highlights the need for evidence-based guidelines for antifungal therapy in neonates.

More Related Videos

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans04:48

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans

Published on: March 24, 2022

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...